Giuseppe Fornarini

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Nivolumab 47%
3. cabozantinib 37%
4. Survival 32%
5. Castration 29%
6. Immunotherapy 28%
7. Prostatic Neoplasms 28%
8. pazopanib 24%
9. Progression-Free Survival 23%
10. Lymphocytes 21%
11. Neutrophils 20%
12. Sunitinib 19%
13. Multicenter Studies 19%
14. Germ Cell and Embryonal Neoplasms 17%
15. Neoplasms 16%
16. Therapeutics 15%
17. Coronavirus Infections 14%
18. Databases 14%
19. Urologic Neoplasms 13%
20. Safety 13%
21. Human Influenza 13%
22. Confidence Intervals 13%
23. tivozanib 13%
24. Carcinoma 13%
25. Compassionate Use Trials 12%
26. Severe Acute Respiratory Syndrome 12%
27. Disease Outbreaks 12%
28. Biomarkers 12%
29. Radium-223 12%
30. Retrospective Studies 12%
31. Nephrectomy 11%
32. Inflammation 11%
33. Neoplasm Metastasis 10%
34. Everolimus 10%
35. Medical Oncology 10%
36. cabazitaxel 10%
37. Clinical Audit 9%
38. Pandemics 9%
39. Oncologists 8%
40. Axitinib 8%
41. Coronavirus 8%
42. Time-to-Treatment 8%
43. Bone and Bones 8%
44. Disease Progression 8%
45. Seminoma 8%
46. Pancreatic Neoplasms 8%
47. Kidney 7%
48. Drug Therapy 7%
49. Positron Emission Tomography Computed Tomography 7%
50. Fluorodeoxyglucose F18 7%